Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I study
Summary: BAT6026 is a fully human IgG1 OX40 monoclonal antibody. This was a multicenter, open-label, dose escalation, and dose expansion phase I study of BAT6026 conducted in patients with advanced solid tumors who failed standard treatment. Patients received BAT6026 injections ranging from 0.01–10...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225005310 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|